|
US5266575A
(en)
*
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
|
US5395937A
(en)
*
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
EP0708772B1
(de)
*
|
1993-07-15 |
2000-08-23 |
Minnesota Mining And Manufacturing Company |
IMIDAZO [4,5-c]PYRIDIN-4-AMINE
|
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US5482936A
(en)
*
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
US6133547A
(en)
*
|
1996-09-05 |
2000-10-17 |
Medtronic, Inc. |
Distributed activator for a two-dimensional shape memory alloy
|
|
US5939090A
(en)
*
|
1996-12-03 |
1999-08-17 |
3M Innovative Properties Company |
Gel formulations for topical drug delivery
|
|
JPH10298181A
(ja)
*
|
1997-04-25 |
1998-11-10 |
Sumitomo Pharmaceut Co Ltd |
タイプ2ヘルパーt細胞選択的免疫応答抑制剤
|
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
SI1341791T1
(en)
*
|
2000-12-08 |
2005-10-31 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
UA75622C2
(en)
*
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
|
GB0211649D0
(en)
*
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
|
PT1543002E
(pt)
*
|
2002-07-23 |
2006-11-30 |
Teva Gyogyszergyar Zartkoeruen |
Preparação de intermediários 1h-imidazo ( 4,5-c )quinolin-4-aminas via 1h- imidazo (4,5-c ) quinolina-4-ftalimida
|
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
|
WO2005051317A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
|
CA2571360C
(en)
*
|
2004-06-18 |
2014-11-25 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals
|
|
US8080560B2
(en)
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
CA2598656A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
|
WO2006091647A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
|
CA2598695A1
(en)
*
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
|
JP2008538550A
(ja)
|
2005-04-01 |
2008-10-30 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物
|
|
EP1951298A1
(de)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Grippeimpfstoffe mit adjuvantien und zytokin-induzierenden mitteln
|
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
|
KR20080083270A
(ko)
*
|
2005-11-04 |
2008-09-17 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
|
|
ES2420829T3
(es)
|
2005-11-04 |
2013-08-27 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
|
EP3753574A1
(de)
|
2006-01-27 |
2020-12-23 |
Seqirus UK Limited |
Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
|
|
EP2004226A1
(de)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Lagerung von grippeimpfstoffen ohne kühlung
|
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
US8124096B2
(en)
|
2006-07-31 |
2012-02-28 |
3M Innovative Properties Company |
Immune response modifier compositions and methods
|
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
|
ES2536401T3
(es)
|
2006-09-11 |
2015-05-25 |
Novartis Ag |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
|
SG177141A1
(en)
|
2006-12-06 |
2012-01-30 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
KR20100016289A
(ko)
*
|
2007-05-08 |
2010-02-12 |
아스트라제네카 아베 |
면역-조정 특성의 이미다조퀴놀린
|
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
PT2268618E
(pt)
*
|
2008-03-03 |
2015-10-12 |
Novartis Ag |
Compostos e composições moduladores da actividade tlr
|
|
WO2009115917A2
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
|
ES2667054T3
(es)
*
|
2008-03-24 |
2018-05-09 |
Biontech Ag |
Nuevas imidazoquinolinas sustituidas
|
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
MX2011010735A
(es)
|
2009-04-14 |
2012-01-25 |
Novartis Ag |
Composiciones para inmunizacion contra staphylococcus aureus.
|
|
FR2949344A1
(fr)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
Vaccins de protection contre la grippe
|
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
|
EP4218799A1
(de)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
|
|
PL2464658T3
(pl)
|
2009-07-16 |
2015-03-31 |
Novartis Ag |
Immunogeny z Escherichia coli o zniesionej toksyczności
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
WO2011084726A1
(en)
*
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
WO2011084725A1
(en)
*
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
E.coliキャリアタンパク質に結合体化した多糖免疫原
|
|
AU2011258165B2
(en)
|
2010-05-26 |
2016-11-17 |
Selecta Biosciences, Inc. |
Dose selection of adjuvanted synthetic nanocarriers
|
|
CA2801151A1
(en)
|
2010-06-01 |
2011-12-08 |
Novartis Ag |
Concentration of vaccine antigens with lyophilization
|
|
EP2575872B1
(de)
|
2010-06-01 |
2020-08-19 |
Seqirus UK Limited |
Konzentrierung und lyophilisierung von influenza antigene zur impfung
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
ES2531577T3
(es)
|
2010-08-20 |
2015-03-17 |
Novartis Ag |
Conjuntos de agujas para la administración de vacuna soluble contra la gripe
|
|
WO2012061717A1
(en)
|
2010-11-05 |
2012-05-10 |
Selecta Biosciences, Inc. |
Modified nicotinic compounds and related methods
|
|
AU2012211278B2
(en)
|
2011-01-26 |
2016-11-10 |
Glaxosmithkline Biologicals Sa |
RSV immunization regimen
|
|
DK2707385T3
(da)
|
2011-05-13 |
2017-11-20 |
Glaxosmithkline Biologicals Sa |
RSV-F-præfusionsantigener
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
WO2013009564A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Tyrosine ligation process
|
|
EP2776069A1
(de)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Trägermolekül mit einem spr0096- und einem spr2021-antigen
|
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
|
WO2014053521A2
(en)
|
2012-10-02 |
2014-04-10 |
Novartis Ag |
Nonlinear saccharide conjugates
|
|
RS56886B1
(sr)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals Sa |
Antigeni pseudomonasa i kombinacije antigena
|
|
DK2950649T3
(da)
*
|
2013-02-01 |
2020-05-04 |
Wellstat Therapeutics Corp |
Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet
|
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
|
BE1022857A1
(fr)
|
2014-03-26 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Immunisation contre staphylococcus aureus
|
|
MX377916B
(es)
*
|
2014-04-22 |
2025-03-10 |
Hoffmann La Roche |
Compuestos 4-amino-imidazoquinolina.
|
|
KR102581546B1
(ko)
|
2015-03-06 |
2023-09-25 |
에프. 호프만-라 로슈 아게 |
벤즈아제핀 다이카복스아미드 화합물
|
|
KR102161364B1
(ko)
*
|
2015-09-14 |
2020-09-29 |
화이자 인코포레이티드 |
LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
|
|
CN108055842B
(zh)
|
2015-09-17 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
|
|
EP3464274B1
(de)
|
2016-05-23 |
2020-05-27 |
H. Hoffnabb-La Roche Ag |
Benzazepindicarboxamidverbindungen mit sekundärer amidfunktion
|
|
JP6918838B2
(ja)
|
2016-05-23 |
2021-08-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
|
|
JP7012668B2
(ja)
|
2016-06-12 |
2022-02-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
|
|
TWI674261B
(zh)
*
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
BR112019024177A2
(pt)
*
|
2017-05-19 |
2020-06-02 |
Superb Wisdom Limited |
Derivados de resiquimode
|
|
IL312120B2
(en)
|
2017-06-23 |
2025-06-01 |
Birdie Biopharmaceuticals Inc |
Pharmaceutical compositions
|
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|